Animal Study Suggests Acetaminophen May Protect Against Colon Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 5
Volume 9
Issue 5

SAN FRANCISCO-Research conducted at New York Medical College, Valhalla, shows that acetaminophen may prevent early biologic changes that can lead to colon cancer.

SAN FRANCISCO—Research conducted at New York Medical College, Valhalla, shows that acetaminophen may prevent early biologic changes that can lead to colon cancer.

In the study, presented at the American Association for Cancer Research (AACR) annual meeting, rats were given low or high doses of 3,2´dimethyl-4-aminobiphenyl (DMAB), a chemical that mimics suspected human colon carcinogens (heterocyclic amines formed during cooking of protein), and acetaminophen or no acetaminophen.

In the animals given carcinogen alone, cellular changes that are common precursors to colon cancer were seen, in relationship to the dose. When the carcinogen was given after acetaminophen, the animals had significantly less cellular evidence of disease, especially gland cell hypertrophy and karyomegaly.

“In our study, even low levels of acetaminophen showed a powerful protective effect in colon cells exposed to DMAB,” said Gary M. Williams, MD, professor of pathology, New York Medical College, at an AACR poster session. “We noted these effects even in animals exposed to much higher doses of DMAB than a human would ever encounter.”

The study was funded in part by a research grant from McNeil Consumer Healthcare.

Recent Videos
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Related Content